Sasanuma H, Tsuda M, Morimoto S, et al. BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes. Proc Natl Acad Sci U S A. 2018;115(45):E10642-E10651. doi:10.1073/pnas.1803177115.

Saji S, Kawakami M, Hayashi S-I, et al. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene. 2005;24(28):4531-9. doi:10.1038/sj.onc.1208646.

Gallenne T, Ross KN, Visser NL, et al. Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer. Oncotarget. 2017;8(13):20572-20587. doi:10.18632/oncotarget.16244.

Setlur SR, Mertz KD, Hoshida Y, et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst. 2008;100(11):815-25. doi:10.1093/jnci/djn150.

Gupta PB, Kuperwasser C. Contributions of estrogen to ER-negative breast tumor growth. J Steroid Biochem Mol Biol. 2006;102(1-5):71-8. doi:10.1016/j.jsbmb.2006.09.025.

Lamb J, Crawford ED, Peck D, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313(5795):1929-35. doi:10.1126/science.1132939.

Mather KJ, Kim C, Christophi CA, et al. Steroid Sex Hormones, Sex Hormone-Binding Globulin, and Diabetes Incidence in the Diabetes Prevention Program. J Clin Endocrinol Metab. 2015;100(10):3778-86. doi:10.1210/jc.2015-2328.